Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of TJ101 Injection Before and After CMC Change in Healthy Adult Male Subjects
NCT07300436Phase 1Completed
- Sponsor
- TJ Biopharma
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eftansomatropin alfa in growth hormone deficiency (GHD) (2 arms), sponsored by TJ Biopharma. Primary endpoints: Maximum Observed Plasma Concentration at 10 days and Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at 10 days. Started Jan 2026; status: completed.
02
Drugs
eftansomatropin alfa
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT07300436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300436.